US Demand for In Vitro Diagnostic Products to Reach $23 Billion in 2013

US demand for in vitro diagnostic (IVD) products is forecast to increase 5.4 percent annually to $23 billion in 2013.  Clinical chemistry and immunoassay will remain the top two IVD methodologies, the former based on sales of personal blood glucose monitors and test strips and the latter due to the penetration of high value-added chemiluminescent products into infectious disease and drug testing markets.  Nucleic acid testing products will generate the fastest demand gains among IVD products based on throughput, accuracy and speed advantages, especially in the detection of infectious diseases and cancer markers.  Because of increasing blood glucose monitoring among diabetic patients, endocrine condition testing will remain the largest IVD application through 2013 and beyond. These and other trends, including market share and product segmentation, are presented in In Vitro Diagnostics, a new study from The Freedonia Group, Inc., a Cleveland-based industry research firm.

Evolving epidemiological trends and patient care approaches will impact favorably on growth opportunities for most types of IVD products.  The market for clinical chemistry reagents and instruments will benefit from an increasing number of diabetic patients engaging in self-blood glucose monitoring and the expanding use of general health screening in routine patient examinations.  The widening availability of chemiluminescent tests with inherent sensitivity and selectivity advantages will broaden applications for immunoassays in therapeutic drug monitoring, drugs of abuse detection and infectious disease testing.

Due to their ability to quantify heart attack and embolism risk prior to occurrence, hemostasis tests for D-dimer and other cardiac parameters will provide the best growth opportunities among IVD blood testing products.  Demand for nucleic acid diagnostics will expand at a strong pace as next- generation PCR (polymerase chain reaction) and microarray technologies penetrate applications involving the analysis and characterization of complex infections and tumors.  DNA-based forensic, genetic and identity testing will comprise the fastest growing IVD application through 2013 as the vast potential of law enforcement and genetic screening markets begins to produce significant revenues.  Among other IVD products, cellular analysis and anatomical pathology reagents and instruments will post favorable gains. 

The Freedonia Group is a leading international business research company, founded in 1985, that publishes more than 100 industry research studies annually. This industry analysis provides an unbiased outlook and a reliable assessment of an industry and includes product segmentation and demand forecasts, industry trends, demand history, threats and opportunities, competitive strategies, market share determinations and company profiles.